A novel in vivo rabbit model of hypercatabolic critical illness reveals a biphasic neuroendocrine stress response.
暂无分享,去创建一个
G. Van den Berghe | J. Veldhuis | C. Bowers | W. Coopmans | E. van Herck | F. Weekers | M. Michalaki
[1] V. Lenaerts,et al. Growth hormone-releasing activity of hexarelin in humans , 1994, European Journal of Clinical Pharmacology.
[2] S. Anderson,et al. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. , 2001, The Journal of clinical endocrinology and metabolism.
[3] C. Bowers. Unnatural growth hormone-releasing peptide begets natural ghrelin. , 2001, The Journal of clinical endocrinology and metabolism.
[4] Steven M. Pincus,et al. Secretory process regularity monitors neuroendocrine feedback and feedforward signaling strength in humans. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[5] G. Van den Berghe,et al. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. , 2000, The Journal of clinical endocrinology and metabolism.
[6] M. Nakazato,et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.
[7] N R Webster,et al. Increased mortality associated with growth hormone treatment in critically ill adults. , 1999, The New England journal of medicine.
[8] G. Van den Berghe,et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. , 1999, The Journal of clinical endocrinology and metabolism.
[9] A. Rahim,et al. Selective lack of growth hormone (GH) response to the GH-releasing peptide hexarelin in patients with GH-releasing hormone receptor deficiency. , 1999, The Journal of clinical endocrinology and metabolism.
[10] L. J. Groot,et al. Dangerous Dogmas in Medicine: The Nonthyroidal Illness Syndrome , 1999 .
[11] G. Van den Berghe,et al. Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness. , 1999, European journal of endocrinology.
[12] I. Robinson,et al. Effects of growth hormone secretagogues on prolactin release in anesthetized dwarf (dw/dw) rats. , 1998, Endocrinology.
[13] G. Van den Berghe,et al. Clinical review 95: Acute and prolonged critical illness as different neuroendocrine paradigms. , 1998, The Journal of clinical endocrinology and metabolism.
[14] A. Barkan,et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. , 1998, The Journal of clinical endocrinology and metabolism.
[15] C. Ryan,et al. A rabbit model for metabolic studies after burn injury. , 1998, The Journal of surgical research.
[16] G. Van den Berghe,et al. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. , 1998, The Journal of clinical endocrinology and metabolism.
[17] E. Fliers,et al. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. , 1997, The Journal of clinical endocrinology and metabolism.
[18] J. Lorente,et al. Pituitary-thyroid function in patients with septic shock and its relation with outcome. , 1997, European journal of medical research.
[19] G. Van den Berghe,et al. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. , 1997, The Journal of clinical endocrinology and metabolism.
[20] M. Falchi,et al. Effect of acute and chronic inflammation on plasma growth hormone levels in rats. , 1997, Drugs under experimental and clinical research.
[21] G. Van den Berghe,et al. Pituitary responsiveness to GH‐releasing hormone, GH‐releasing peptide‐2 and thyrotrophin‐releasing hormone in critical illness , 1996, Clinical endocrinology.
[22] R. Mcdowell,et al. In vitro characterization of four novel classes of growth hormone-releasing peptide. , 1995, Endocrinology.
[23] C. Lang,et al. Alterations in the insulin-like growth factor system in trauma patients. , 1995, The American journal of physiology.
[24] B. D. Clark,et al. Suppression of thyrotropin-releasing hormone gene expression by interleukin-1-beta in the rat: implications for nonthyroidal illness. , 1994, Neuroendocrinology.
[25] C. Sweep,et al. Different effects of continuous infusion of interleukin-1 and interleukin-6 on the hypothalamic-hypophysial-thyroid axis. , 1994, Endocrinology.
[26] A. Barkan,et al. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. , 1993, The Journal of clinical endocrinology and metabolism.
[27] B. Atac,et al. Hematologic changes in massive burn injury , 1992, Critical care medicine.
[28] J. Verhaeghe,et al. The effects of systemic insulin, insulin-like growth factor-I and growth hormone on bone growth and turnover in spontaneously diabetic BB rats. , 1992, The Journal of endocrinology.
[29] J. Miell,et al. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin–like growth factor‐I , 1991, Clinical endocrinology.
[30] S M Pincus,et al. Approximate entropy as a measure of system complexity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[31] M. Vance,et al. Temporal structure of in vivo growth hormone secretory events in humans. , 1991, The American journal of physiology.
[32] M L Johnson,et al. The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[33] A. Beddoe,et al. Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. , 1987, The Journal of trauma.
[34] J. Billett,et al. Fluid retention and burn survival. , 1987, The Journal of trauma.
[35] S. Wallner,et al. The Anemia of Thermal Injury: Mechanism of Inhibition of Erythropoiesis 1 , 1986, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[36] W. Vale,et al. Involvement of corticotropin-releasing factor and somatostatin in stress-induced inhibition of growth hormone secretion in the rat. , 1985, Endocrinology.
[37] K. Swedberg,et al. Endogenous catecholamine levels in chronic heart failure. Relation to the severity of hemodynamic abnormalities. , 1985, The American journal of medicine.
[38] R. Phillips,et al. Circulating thyroid hormone changes in acute trauma: prognostic implications for clinical outcome. , 1984, The Journal of trauma.
[39] J. Kinney,et al. Effect of an anabolic steroid on nitrogen balance and amino acid patterns after total hip replacement. , 1982, The Journal of trauma.
[40] R. Utiger. Decreased extrathyroidal triiodothyronine production in nonthyroidal illness: benefit or harm? , 1980, The American journal of medicine.
[41] R. Hoffenberg,et al. Effects of surgical stress and corticotrophin on the peripheral metabolism of thyroid hormones in rabbits. , 1979, The Journal of endocrinology.
[42] H. Selye,et al. Shift in adenohypophyseal activity during chronic intermittent immobilization of rats. , 1976, Neuroendocrinology.
[43] W. Odell,et al. Physiological control of growth hormone in the rabbit. , 1974, Neuroendocrinology.